Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) fell 4.6% during mid-day trading on Monday . The company traded as low as $7.86 and last traded at $7.87. 989,264 shares changed hands during trading, a decline of 74% from the average session volume of 3,823,179 shares. The stock had previously closed at $8.25.
Wall Street Analysts Forecast Growth
Several analysts have commented on ALT shares. UBS Group began coverage on Altimmune in a research report on Tuesday, November 12th. They issued a "buy" rating and a $26.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $20.00.
Read Our Latest Stock Report on ALT
Altimmune Price Performance
The stock has a market capitalization of $551.93 million, a price-to-earnings ratio of -5.01 and a beta of 0.15. The stock has a 50 day moving average price of $7.93 and a 200-day moving average price of $7.10.
Altimmune (NASDAQ:ALT - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period last year, the firm earned ($0.39) EPS. As a group, research analysts forecast that Altimmune, Inc. will post -1.36 earnings per share for the current year.
Institutional Investors Weigh In On Altimmune
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Larson Financial Group LLC acquired a new stake in Altimmune during the third quarter worth about $31,000. PFG Investments LLC acquired a new stake in shares of Altimmune during the 2nd quarter worth approximately $67,000. Principal Financial Group Inc. purchased a new stake in shares of Altimmune during the 2nd quarter valued at approximately $70,000. Verus Capital Partners LLC acquired a new position in Altimmune in the second quarter valued at approximately $82,000. Finally, XTX Topco Ltd acquired a new position in Altimmune in the second quarter valued at approximately $96,000. Institutional investors and hedge funds own 78.05% of the company's stock.
About Altimmune
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
See Also
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
